Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management
AbstractNeuropathic pain afflicts a large percentage of the global population. This form of chronic, intractable pain arises when the peripheral or central nervous systems are damaged, either directly by lesion or indirectly through disease. The comorbidity of neuropathic pain with other diseases, including diabetes, cancer, and AIDS, contributes to a complex pathogenesis and symptom profile. Because most patients present with neuropathic pain refractory to current first-line therapeutics, pharmaceuticals with greater efficacy in pain management are highly desired. In this review we discuss the growing application of ω-conotoxins, small peptides isolated from Conus species, in the management of neuropathic pain. These toxins are synthesized by predatory cone snails as a component of paralytic venoms. The potency and selectivity with which ω-conotoxins inhibit their molecular targets, voltage-gated Ca2+ channels, is advantageous in the treatment of neuropathic pain states, in which Ca2+ channel activity is characteristically aberrant. Although ω-conotoxins demonstrate analgesic efficacy in animal models of neuropathic pain and in human clinical trials, there remains a critical need to improve the convenience of peptide drug delivery methods, and reduce the number and severity of adverse effects associated with ω-conotoxin-based therapies. View Full-Text
Share & Cite This Article
Hannon, H.E.; Atchison, W.D. Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management. Mar. Drugs 2013, 11, 680-699.
Hannon HE, Atchison WD. Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management. Marine Drugs. 2013; 11(3):680-699.Chicago/Turabian Style
Hannon, Heidi E.; Atchison, William D. 2013. "Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management." Mar. Drugs 11, no. 3: 680-699.